Invivyd Target of Unusually High Options Trading (NASDAQ:IVVD)

Invivyd, Inc. (NASDAQ:IVVD) saw some unusual options trading on Thursday. Investors purchased 2,267 call options on the stock. This is an increase of 463% compared to the average volume of 403 call options.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Morgan Stanley dropped their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a report on Tuesday. Finally, D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a report on Monday. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $7.89.

Insider Activity at Invivyd

In other news, Director Terrance Mcguire sold 119,805 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $0.42, for a total value of $50,318.10. Following the completion of the transaction, the director now directly owns 3,568,274 shares in the company, valued at $1,498,675.08. This trade represents a 3.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 816,466 shares of company stock valued at $423,214 in the last ninety days. Corporate insiders own 17.90% of the company’s stock.

Institutional Trading of Invivyd

A number of institutional investors have recently made changes to their positions in IVVD. Barclays PLC lifted its position in Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after buying an additional 75,780 shares in the last quarter. State Street Corp grew its stake in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after buying an additional 35,904 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd in the third quarter valued at $27,000. Cubist Systematic Strategies LLC grew its stake in shares of Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after buying an additional 53,499 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Invivyd during the 2nd quarter worth $421,000. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Price Performance

Shares of NASDAQ:IVVD opened at $1.98 on Friday. The business’s 50 day moving average price is $0.55 and its 200-day moving average price is $0.83. The firm has a market capitalization of $236.85 million, a PE ratio of -1.01 and a beta of 0.61. Invivyd has a 1 year low of $0.35 and a 1 year high of $5.10.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.